Nitrolingual is owned by Pohl Boskamp.
Nitrolingual contains Nitroglycerin.
Nitrolingual has a total of 1 drug patent out of which 0 drug patents have expired.
Nitrolingual was authorised for market use on 31 October, 1985.
Nitrolingual is available in spray, metered;sublingual dosage forms.
Nitrolingual can be used as method of treating angina pectoris.
The generics of Nitrolingual are possible to be released after 12 March, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7872049 | POHL BOSKAMP | Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate |
Mar, 2029
(6 years from now) |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 31 October, 1985
Treatment: Method of treating angina pectoris
Dosage: SPRAY, METERED;SUBLINGUAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic